MedTrace Logo

Turkish Version of The Lower Limb Assessment Score

NCT05558202 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2023-08-02

No results posted yet for this study

Summary

Hypermobility is more than normal joint laxity, mobility, and range of motion. It is characterized by increased laxity and fragility of connective tissues. Symptoms from hypermobility can begin at any age and affect women more than men. People are at higher risk than other people. It is stated that hypermobility is an important factor in orthopedic injuries and diseases. Individuals with hypermobility have more frequent orthopedic complaints and the problems are usually idiopathic and chronic. Studies have reported that proprioception and musculoskeletal reflex function may be affected independently of symptoms in hypermobile individuals. Therefore, evaluating hypermobility is very important in preventing hypermobility-related problems and injuries and developing appropriate treatment methods. Although the Beighton score is the most commonly used scoring method to determine hypermobility, it may be insufficient to determine hypermobility of the lower extremities. The Lower Limb Assessment Score (LLAS) has been reported to be one of the most appropriate scoring methods for assessing lower extremity hypermobility in the literature. The aim of this study is to adapt LLAS to Turkish and measure its validity and reliability.

Conditions

  • Hypermobility, Joint

Interventions

OTHER

Turkish validity and reliability

1. Explanation of the Turkish version of the scale. 2. Translating the Turkish version of the scale into English to ensure consistency with the original scale. 3. First application of scales to participants by two examiners separately. 4. Second application of the scales to the participants by one examiner. 5. Statistical analysis and scaling

Sponsors & Collaborators

  • Kutahya Health Sciences University

    lead OTHER

Principal Investigators

  • Emrah Afsar, Phd · Kutahya Health Sciences University

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2022-10-30
Completion
2022-12-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05558202 on ClinicalTrials.gov